Zealand Pharma A/S (ZLDPF PINK) stock market data APIs
$50.0314
0.28(0.6%)
as of June 5, 2026
Try our APIs with
free plan!
Zealand Pharma A/S Financial Data Overview
Price chart is built with
Anychart
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Prev. Close
50.0314
Open
50.311
High
50.6169
Low
49.8673
52 wk Range
35.931-83.12
Market Cap
2 715 M
P/E Ratio
2.7918
Shares Outstanding
70 077 K
Revenue
9 241 M
EPS
-0.8738
Beta
0.589
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zealand Pharma A/S data using free add-ons & libraries
Get Zealand Pharma A/S Fundamental Data
Zealand Pharma A/S Fundamental data includes:
- Net Revenue: 9 241 M
- EBITDA: 6 799 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -9.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zealand Pharma A/S News
New
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
Key Points Zealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients. That's good news for Eli Lilly and Novo Nordisk, ...
Zealand Pharma tumbles 24% as weight-loss drug data sparks safety fears
* Shares of Zealand Pharma (ZLDPF [https://seekingalpha.com/symbol/ZLDPF]), the weight-loss drug developer, tumbled as much as 26% on Monday after fresh data from its experimental treatment sparked ...
Why The Narrative Around Zealand Pharma (CPSE:ZEAL) Is Shifting After Target Resets And Trial Updates
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma’s modeled fair value has been updated to DKK 525.73 from DKK 519.07. Recen...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Zealand Pharma Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizi...
Get Zealand Pharma A/S fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
